BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Almac Group Launches New Histone Reagents Catalogue and Custom Synthesis Service


9/17/2012 6:43:29 AM

September 17, 2012 -- Almac has today announced the launch of a new reagent offering based on the provision of homogeneous full length histones with defined patterns of modification. The histone reagents will prove a highly valuable tool for researchers seeking to prosecute key drug targets in the field of epigenetics.

Almac’s unique array of platform technologies for the chemical synthesis of proteins, enable the provision of pure full-length natural histones containing a wide variety of post-translational modifications at any specified site(s) within the protein. The reagents are set to be offered through a catalogue of modified histones and additionally as a custom synthesis service to meet bespoke customer demands. Almac believes this will provide the epigenetic research community with a unique source of enabling research tools. The modified histone reagent provision complements Almac’s growing range of FLEXYTE® FLT assays for epigenetic targets.

‘This is a first class example of how Almac can harness its unique protein synthesis capability to provide a much needed source of tools to the epigenetic research field. I am delighted that we are able to offer such capabilities.’ commented Dr Charles Shields, Vice President of Peptide and Protein Technologies at Almac.

About Almac

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.

For more information about the Almac Group, please visit www.almacgroup.com or e-mail info@almacgroup.

Tristan Jervis

Managing Partner

Holborn Gate, 26 Southampton Buildings

London WC2A 1BP

Telephone: +44 (0)207 861 3838

Direct: +44 (0)207 861 3019

Fax: +44 (0)207 861 3839

E-mail: t.jervis@defacto.com

www.defacto.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES